Lexeo Therapeutics, Inc.
Lexeo Therapeutics, Inc. (Nasdaq: LXEO) is a clinical-stage genetic medicine company developing gene therapies for cardiovascular and neurodegenerative diseases. Its cardiovascular portfolio targets genetically defined conditions, including Friedreich ataxia cardiomyopathy, PKP2-related arrhythmogenic cardiomyopathy,… From the company’s description.
In fiscal 2025, Lexeo Therapeutics, Inc. reported a net loss of $99.96M. Operations used $98.56M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Lexeo Therapeutics, Inc. does
In the company’s own words
Lexeo Therapeutics, Inc. (Nasdaq: LXEO) is a clinical-stage genetic medicine company developing gene therapies for cardiovascular and neurodegenerative diseases. Its cardiovascular portfolio targets genetically defined conditions, including Friedreich ataxia cardiomyopathy, PKP2-related arrhythmogenic cardiomyopathy, DSP cardiomyopathy, and TNNI3-related hypertrophic cardiomyopathy. The lead candidates, LX2006 and LX2020, are in Phase 1/2 clinical trials; LX2021 and LX2022 are in preclinical development. The company’s candidates are designed to deliver functional genes to address underlying genetic causes, and its most advanced programs use an AAVrh10 vector. Lexeo also develops therapies for APOE4-associated Alzheimer’s disease, including LX1001, which completed a Phase 1/2 trial, and two early-stage candidates. It is seeking business development opportunities for its Alzheimer’s portfolio. Lexeo retains exclusive worldwide development and commercialization rights to its product candidates and programs.
Company details
- Sector
- Health Care
- Industry (SIC)
- Biological Products
- Headquarters
- NEW YORK, NY
- Fiscal year end
- December
- CIK
- 1907108
- SIC
- 2836
Financial performance, year by year
Fiscal 2023–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Lexeo Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Lexeo Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Lexeo Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Lexeo Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Lexeo Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”